Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome. Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurinfor the Prevention of Arterial Even ...
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome (vEDS) Confirmed With COL3A1 Mutations, Followed by an Open Label Extension (OLE) A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Enzastaurinfor the Prevention o ...
A study to investigate the efficacy, safety, and pharmacokinetics (PK) of enzastaurin for the prevention of arterial events in patients with vEDS confirmed with COL3A1 mutations A study to investigate the efficacy, safety, and pharmacokinetics (PK) of enzastaurinfor the prevent ...
A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE) - PREVEnt (Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome Trial) A multicenter, randomized, double-blind, placebo-controlled study of enzastaurinfor the prevention o ...
vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations MedDRA version: 20.0;Level: PT;Classification code 10014316;Term: Ehlers-Danlos syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations MedDRA version: 20.0;Level: P ...